Navigation Links
Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment

COPENHAGEN, June 3, 2007 - Genmab A/S (CSE: GEN) announced today pre-clinical data illustrating its fully human HuMax-EGFr™ (zalutumumab) antibody may have broad potential to treat cancers that over-express several types of EGFr (epidermal growth factor receptor).

Recently, mutations which appear to alter the signaling ability of EGFr have been identified in tumors from lung cancer patients. Such mutations may be a critical factor in the potential success of EGFr-directed treatments in lung cancer.

In a novel cancer cell laboratory model, HuMax-EGFr effectively inhibited the growth of tumor cells that express both mutated or normal EGF receptors. This inhibition occurred through different mechanisms of action including direct inhibition of cancer cell growth and an immune cell-mediated killing activity known as antibody dependent cell-mediated cytotoxicity (ADCC).

Genmab scientists also used the model to test the effects of tyrosine kinase inhibitors (TKI) such as the marketed products Iressa and Tarceva on EGFr-expressing tumor cells. Tumor cells expressing various mutated EGFr varied strongly in their sensitivity to TKI therapy, whereas no differences in efficacy where observed for HuMax-EGFr.

"This pre-clinical data indicates that HuMax-EGFr may have more potential in the treatment of some types of cancer, such as lung cancer, than tyrosine kinase inhibitors," said Lisa N. Drakeman, Ph.D., Chief of Genmab.

These data will be presented today in a poster session at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA.


'"/>




Page: 1

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genmab HuMax EGFr Shows Broad Potential Cancer Treatment
(Date:3/2/2015)... MENLO PARK, Calif. , March 2, 2015 /PRNewswire/ ... medical device company that has developed and commercialized an ... pain, today announced that Brad Vale , PhD, ... (JJDC), has been appointed to its Board of Directors, ... has over 30 years of experience in developing, commercializing ...
(Date:3/2/2015)... 2, 2015  BC Technical, the nation,s leading ... Eclipse Systems, a Nuclear Imaging service company providing ... of their ongoing vision to provide the best, ... BC Technical continues to expand their reach and ... add valuable resources and knowledge in addition to ...
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
Breaking Medicine Technology:Nevro Appoints Dr. Brad Vale to its Board of Directors 2BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5
... Sept. 7, 2011 Cyberonics, Inc. (NASDAQ: CYBX ... will participate in the 2011 UBS Global Life Sciences Conference ... Dan Moore, Cyberonics, President and Chief Executive Officer, will speak ...  A live audio webcast of the presentation can be accessed ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... will present a company update at the Morgan Stanley Global ... at 10:55 a.m. ET.   Interested parties may ... the investor section of the BioMarin website, www.BMRN.com . ...
Cached Medicine Technology:BioMarin to Present at the Morgan Stanley Global Healthcare Conference 2
(Date:3/2/2015)... Mirena IUD lawsuits ( http://www.mirenalawsuit2014.com/ ) ... by the long-acting birth control device continue to move ... according to Bernstein Liebhard LLP. In an Order ... on February 24th, the Court ruled that a Mirena ... pursue her lawsuit, which accuses Bayer Healthcare Pharmaceuticals of ...
(Date:3/2/2015)... VIENNA,VA (PRWEB) March 02, 2015 Today the ... Injury Awareness Month, a time to recognize and support the ... disabilities. , Each year BIAA leads the nation in ... during the month of March. The theme for the 2015 ... Alone campaign provides a platform for educating the general public ...
(Date:3/2/2015)... 2015 GBCHealth, a prominent business ... sector activities and investments in global health issues, ... new members to serve on the organization’s Board ... Chief Strategist and Co-founder of Partners In Health, ... Huma Abbasi, General Manager of Global Health and ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Ticket Down ... at the Hollywood Bowl . This popular site has ... appreciation promo code JIMMY-BUFFETT-2015 for added savings. , Parrotheads ... favorite performer will be headlining at the Hollywood Bowl ... will be on Thursday, October 22nd and it will ...
(Date:3/2/2015)... FL (PRWEB) March 02, 2015 While ... with Title VI of the Civil Rights Act, the ... and hearing loss are bringing light to the value ... statistics reveal that nearly 1 in 20 U.S. children ... in 10 in some major cities.(1) Stratus Video ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 4Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4
... for a child. But stress and fear, and the ... reduced with simple means: drawings, continuity and dialogue. This ... at the University of Gothenburg, Sweden. Berith Wennstrm ... they experienced being in hospital and undergoing surgery. The ...
... Dotinga HealthDay Reporter , TUESDAY, Dec. 20 ... training, which teaches people to push away troublesome thoughts, ... similar diseases. Patients in Norway who received the ... who didn,t receive the training, but researchers found they ...
... Discovery Campaign, which seeks to further the growth ... discovery, announced a major corporate pledge to that ... and laboratory diagnostic equipment and information technology and ... pledged $200,000, as a "Pioneer" Supporter. ...
... with spirits drinkers, have been shown to have higher ... diet, be more physically active, and have other characteristics ... epidemiologic studies have been inconsistent in showing that, after ... have lower risk of cardiovascular disease and mortality than ...
... Calif. -- A program for women at risk of ... annually in health care costs if implemented nationwide, according ... American College of Obstetricians and Gynecologists, journal, Obstetrics ... the Kaiser Permanente Early Start program follows a 2008 ...
... Medicine received a $6.75 million Program Project Grant from ... Diseases (NIDDK) to study the role of innate immunity ... focused their attention on the role of lymphocytes and ... disease, a chronic debilitating disease affecting more than one ...
Cached Medicine News:Health News:Different methods can reduce hospital fear in children 2Health News:Mindfulness Training May Help Arthritis Patients Cope 2Health News:Study finds Kaiser Permanente Early Start program could save US billions in health costs 2Health News:$6.75 million awarded to Case Western Reserve to study IBD 2
The Bio-Quant CK-MB test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of,CK-MB in human serum specimens as an aid in the diagnosis of myocar...
... an all new, completely re-engineered high performance PTCA ... LOWEST CROSSING PROFILE PTCA products available at ... of only 0.17. Atriums all new HyperLite LX ... ever!, ,Atriums new "Dura-Blend tip technology is a ...
... Through its unique and patented design, ... and trunk cables between patients and ... allowing freedom of movement throughout the ... the LifeSync(R) System employs two-way radios ...
... InstaTest AFP is an immunochromatographic in vitro ... (AFP) in human serum. AFP is a ... to 74,000 D. Its normal concentration in ... are associated with hepatoma and ovarian, testicular ...
Medicine Products: